Shares of Insys Therapeutics (NASDAQ:INSY) rose 20% today, after the company posted strong second-quarter results for its cancer-related pain medicine, Subsys. After operating at a loss last year, the 38% sales growth of the drug this year helped propel Insys to making a $24 million profit this year. Shares of the stock have doubled year to date and are up 600% over the past 12 months.
In this video, Motley Fool health-care analyst David Williamson looks at Insys. With sales of Subsys having now surpassed all estimates, this is one that he will definitely have on his radar going forward.
Looking for more portfolio-changing growth in 2014?
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.
David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.